1. Home
  2. SNDX vs TSLX Comparison

SNDX vs TSLX Comparison

Compare SNDX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$24.21

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$18.27

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDX
TSLX
Founded
2005
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
2014
2011

Fundamental Metrics

Financial Performance
Metric
SNDX
TSLX
Price
$24.21
$18.27
Analyst Decision
Strong Buy
Buy
Analyst Count
12
9
Target Price
$84.17
$21.72
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
05-04-2026
04-29-2026
Dividend Yield
N/A
11.55%
EPS Growth
11.56
N/A
EPS
N/A
1.81
Revenue
$172,352,000.00
N/A
Revenue This Year
$112.05
N/A
Revenue Next Year
$51.24
$1.92
P/E Ratio
N/A
$9.84
Revenue Growth
627.84
N/A
52 Week Low
$8.59
$16.99
52 Week High
$25.44
$25.17

Technical Indicators

Market Signals
Indicator
SNDX
TSLX
Relative Strength Index (RSI) 65.43 45.33
Support Level $19.46 $17.15
Resistance Level $25.16 $22.46
Average True Range (ATR) 1.09 0.55
MACD 0.08 0.11
Stochastic Oscillator 72.18 66.67

Price Performance

Historical Comparison
SNDX
TSLX

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: